Adult Malignant Glioma Therapeutics Global Market Report 2024

Description

The field of adult malignant glioma therapeutics focuses on treating brain tumors that originate in the glial cells of the brain or spinal cord, particularly in adults. This encompasses various treatment options designed to enhance the quality of life and extend the survival of individuals affected by malignant gliomas.

The primary subtypes of adult malignant glioma therapeutics include glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme (GBM), known for its aggressive nature, involves rapid tumor growth and the infiltration of neighboring brain tissue, typically without distant organ metastasis. Therapeutic interventions in this domain encompass chemotherapy, targeted therapy, radiotherapy, and other modalities. These treatments are administered in various healthcare settings, including hospitals, specialty clinics, and cancer and radiation therapy centers.

The adult malignant glioma therapeutics market research report is one of a series of new reports from The Business Research Company that provides adult malignant glioma therapeutics market statistics, including adult malignant glioma therapeutics industry global market size, regional shares, competitors with a adult malignant glioma therapeutics market share, detailed adult malignant glioma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the adult malignant glioma therapeutics industry. This adult malignant glioma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adult malignant glioma therapeutics market size has grown rapidly in recent years. It will grow from $2.03 billion in 2023 to $2.25 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The historical growth in the field of adult malignant glioma therapeutics can be attributed to factors such as an increase in incidence rates, the influence of patient advocacy initiatives, and the adoption of personalized medicine approaches. These factors have contributed to advancements in understanding the disease and tailoring treatment strategies to individual patients, thereby influencing the positive trajectory in this therapeutic domain.

The adult malignant glioma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.23 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The anticipated growth in the forecast period for adult malignant glioma therapeutics can be attributed to advancements in immunotherapy, targeted therapies, biomarker discoveries, the application of liquid biopsy techniques, and the expansion of access programs. These trends reflect a shift towards patient-centric drug development, accelerated regulatory pathways such as fast-track and breakthrough designations, innovations in drug delivery systems, collaborative research initiatives, and the integration of artificial intelligence in enhancing treatment approaches.

The upward trajectory in brain tumor cases is anticipated to be a significant driver in propelling the growth of the adult malignant glioma therapeutics market. Brain tumors represent anomalous masses of tissue characterized by the abnormal proliferation and unchecked growth of cells, circumventing the usual regulatory mechanisms. Adult malignant glioma, a specific type of brain tumor, comprises cells exhibiting abnormal and uncontrolled growth patterns. Treatment for adult malignant glioma typically involves a combination of surgical procedures, radiation therapy, and chemotherapy. Illustrating this trend, as per the American Cancer Society's January 2023 report, the number of cases related to brain and nervous system cancers escalated to 24,810 in 2023, demonstrating a notable 3.85% increase from 23,890 recorded in 2020. Thus, the mounting instances of brain tumors serve as a driving force behind the expansion of the adult malignant glioma therapeutics market.

The infusion of government funding dedicated to brain cancer research is poised to significantly propel the growth trajectory of the adult malignant glioma therapeutics market moving forward. Government funding entails financial support disbursed by governmental bodies at various levels-federal, state, or local-towards initiatives, programs, projects, organizations, or individuals. The allocation of government funds for brain cancer research holds substantial promise for advancing adult malignant glioma therapeutics. This funding can significantly aid in the development of innovative treatments, tailored drug design, focusing on pyrimidine synthesis, and expediting orphan drug approvals. For example, in June 2023, the Australian Department of Health and Aged Care initiated the Australian Brain Cancer Mission, committing a fund of $136.66 million specifically aimed at supporting brain cancer research endeavors. The primary objective of this initiative is to double survival rates and enhance the overall quality of life for brain cancer patients, including those with anaplastic astrocytoma. Consequently, government funding geared towards brain cancer research stands as a pivotal driver propelling the adult malignant glioma therapeutics market.

The high expenses associated with chemotherapy stand as a significant constraint impacting the global adult malignant glioma therapeutics market. Chemotherapy involves the utilization of potent medications, particularly anti-cancer drugs, aimed at destroying rapidly dividing cells within the body. The fluctuating costs of chemotherapy, influenced by specific drugs and cancer types, often act as a deterrent for patients seeking access to treatment, potentially affecting their overall health and financial well-being. For instance, as reported by the National Cancer Institute in July 2022, the average expenses for medical care and medications during the first year following a cancer diagnosis exceeded $42,000, with certain procedures reaching costs surpassing $1 million. Consequently, the steep cost of chemotherapy is poised to negatively impact the adult malignant glioma therapeutics market.

Leading companies within the adult malignant glioma therapeutics market are actively engaged in the development of innovative products, notably small molecule targeted degraders, aimed at providing enhanced and dependable customer service. Small-molecule targeted degraders represent a class of drugs employing small molecules to induce the degradation of specific proteins by targeting both the protein of interest (POI) and an E3 ubiquitin ligase. For instance, in February 2023, Beactica Therapeutics AB, a precision oncology company based in Sweden, attained orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17 designed to treat glioblastoma (GBM). BEA-17 functions as a small-molecule targeted degrader targeting the epigenetic enzyme LSD1 and its co-factor CoREST, implicated in the pathogenesis of various cancers, including GBM. The drug works by degrading LSD1 and CoREST, leading to the reactivation of tumor suppressor genes and inhibiting the growth of cancer cells. This innovative approach holds promise in advancing treatment options within the adult malignant glioma therapeutics market.

In May 2021, Novocure Ltd., a Swiss-based pioneer in developing and producing innovative oncology therapies, formed a collaboration with GT Medical Technologies Inc. This partnership seeks to merge Tumor Treating Fields (TTFields) with GT Medical Technologies' GammaTile Surgically Targeted Radiation Therapy (STaRT) in the management of recurrent glioblastoma (GBM). Novocure and GT Medical Technologies aim to commence a phase 2 pilot study specifically designed to assess the safety and efficacy of neo-adjuvant TTFields, followed by resection, GammaTile Therapy, and adjuvant TTFields for treating recurrent GBM. GT Medical Technologies Inc., headquartered in the United States, specializes in providing surgically targeted radiation therapy catering to various malignant brain tumors in adult patients.

Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan plc, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.

North America was the largest region in the adult malignant glioma therapeutics market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the adult malignant glioma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The adult malignant glioma therapeutics market consists of revenues earned by entities by providing services such as resection, subtotal resection, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The adult malignant glioma therapeutics market consists of sales of temozolomide, bevacizumab, carmustine, and monoclonal antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adult Malignant Glioma Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adult malignant glioma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adult malignant glioma therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adult malignant glioma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Type Of Disease: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma; Other Types
2) By Therapy: Chemotherapy; Targeted Therapy; Radiotherapy; Other Therapies
3) By End-User: Hospitals; Specialty Clinics; Cancer And Radiation Therapy Centers; Other End Users
Companies Mentioned: Johnson & Johnson Private Limited; Pfizer Inc.; Bio-Rad Laboratories Inc.; F. Hoffmann-La Roche Ltd.; Allergan plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13391

1. Executive Summary

2. Adult Malignant Glioma Therapeutics Market Characteristics

3. Adult Malignant Glioma Therapeutics Market Trends And Strategies

4. Adult Malignant Glioma Therapeutics Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Adult Malignant Glioma Therapeutics Market Size and Growth

5.1. Global Adult Malignant Glioma Therapeutics Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Adult Malignant Glioma Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Adult Malignant Glioma Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Adult Malignant Glioma Therapeutics Market Segmentation

6.1. Global Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma
Other Types
6.2. Global Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Chemotherapy
Targeted Therapy
Radiotherapy
Other Therapies
6.3. Global Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Specialty Clinics
Cancer And Radiation Therapy Centers
Other End Users

7. Adult Malignant Glioma Therapeutics Market Regional And Country Analysis

7.1. Global Adult Malignant Glioma Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Adult Malignant Glioma Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Adult Malignant Glioma Therapeutics Market

8.1. Asia-Pacific Adult Malignant Glioma Therapeutics Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Adult Malignant Glioma Therapeutics Market

9.1. China Adult Malignant Glioma Therapeutics Market Overview
9.2. China Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Adult Malignant Glioma Therapeutics Market

10.1. India Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Adult Malignant Glioma Therapeutics Market

11.1. Japan Adult Malignant Glioma Therapeutics Market Overview
11.2. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Adult Malignant Glioma Therapeutics Market

12.1. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Adult Malignant Glioma Therapeutics Market

13.1. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Adult Malignant Glioma Therapeutics Market

14.1. South Korea Adult Malignant Glioma Therapeutics Market Overview
14.2. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Adult Malignant Glioma Therapeutics Market

15.1. Western Europe Adult Malignant Glioma Therapeutics Market Overview
15.2. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Adult Malignant Glioma Therapeutics Market

16.1. UK Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Adult Malignant Glioma Therapeutics Market

17.1. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Adult Malignant Glioma Therapeutics Market

18.5. France Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.6. France Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.7. France Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Adult Malignant Glioma Therapeutics Market

19.9. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.10. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.11. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Adult Malignant Glioma Therapeutics Market

20.13. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.14. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Adult Malignant Glioma Therapeutics Market

21.1. Eastern Europe Adult Malignant Glioma Therapeutics Market Overview
21.2. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Adult Malignant Glioma Therapeutics Market

22.1. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Adult Malignant Glioma Therapeutics Market

23.1. North America Adult Malignant Glioma Therapeutics Market Overview
23.2. North America Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Adult Malignant Glioma Therapeutics Market

24.1. USA Adult Malignant Glioma Therapeutics Market Overview
24.2. USA Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Adult Malignant Glioma Therapeutics Market

25.1. Canada Adult Malignant Glioma Therapeutics Market Overview
25.2. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Adult Malignant Glioma Therapeutics Market

26.1. South America Adult Malignant Glioma Therapeutics Market Overview
26.2. South America Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Adult Malignant Glioma Therapeutics Market

27.1. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Adult Malignant Glioma Therapeutics Market

28.1. Middle East Adult Malignant Glioma Therapeutics Market Overview
28.2. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Adult Malignant Glioma Therapeutics Market

29.1. Africa Adult Malignant Glioma Therapeutics Market Overview
29.2. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Adult Malignant Glioma Therapeutics Market Competitive Landscape And Company Profiles

30.1. Adult Malignant Glioma Therapeutics Market Competitive Landscape
30.2. Adult Malignant Glioma Therapeutics Market Company Profiles
- 30.2.1. Johnson & Johnson Private Limited
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Pfizer Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Bio-Rad Laboratories Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. F. Hoffmann-La Roche Ltd.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Allergan plc
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Adult Malignant Glioma Therapeutics Market Other Major And Innovative Companies

31.1. AbbVie Inc.
31.2. Novartis AG
31.3. Bayer AG
31.4. Merck & Co Inc.
31.5. GlaxoSmithKline plc
31.6. Bristol-Myers Squibb Company
31.7. Abbott Laboratories
31.8. AstraZeneca plc
31.9. Eli Lilly and Company
31.10. Amgen Inc.
31.11. Teva Pharmaceutical Industries Ltd.
31.12. GT Medical Technologies Inc.
31.13. Lupin Limited
31.14. Mylan NV
31.15. Sanofi SA

32. Global Adult Malignant Glioma Therapeutics Market Competitive Benchmarking

33. Global Adult Malignant Glioma Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Adult Malignant Glioma Therapeutics Market

35. Adult Malignant Glioma Therapeutics Market Future Outlook and Potential Analysis

35.1 Adult Malignant Glioma Therapeutics Market In 2028 - Countries Offering Most New Opportunities
35.2 Adult Malignant Glioma Therapeutics Market In 2028 - Segments Offering Most New Opportunities
35.3 Adult Malignant Glioma Therapeutics Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer